Teclistamab showed promising clinical activity and a tolerable safety profile in patients with relapsed/refractory multiple myeloma.
Gina Mauro
Advertisement
Articles by Gina Mauro
The FDA has granted a breakthrough therapy designation to zanidatamab for the treatment of patients with HER2 gene–amplified biliary tract cancer who have received prior therapy.
The FDA has approved the FoundationOne CDx (F1CDx) comprehensive genomic test as a companion diagnostic for larotrectinib (Vitrakvi) to identify patients with NTRK1/2/3 gene fusions across all solid tumors.
The FDA granted fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the treatment of chronic lymphocytic leukemia.
Advertisement
Latest Updated Articles
FDA Fast Tracks Combination Therapy for Chronic Lymphocytic LeukemiaPublished: October 22nd 2020 | Updated:
FDA Approves FoundationOne CDx Genomic Test as Companion Diagnostic for LarotrectinibPublished: October 26th 2020 | Updated:
Zanidatamab Gets FDA Breakthrough Designation for HER2 Gene–Amplified Biliary Tract CancerPublished: December 1st 2020 | Updated:
Treatment for Relapsed/Refractory Multiple Myeloma Shows Promising Clinical Activity, SafetyPublished: March 9th 2021 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Breaking News: CVS Buys Rite Aid, Bartell Drugs
2
Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
3
FDA Approves 1-Minute HIV Self-Test
4
Young Women With Symptomatic Long COVID At Higher Risk of POTS
5
